pocketful logo
Colinz Laboratories Ltd logo

Colinz Laboratories Ltd

NSE: BSE: 531210

43.47

(4.75%)

Wed, 18 Mar 2026, 01:37 am

Colinz Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    5.41

  • Net Profit

    0.50

  • P/B

    1.93

  • Sector P/E

    39.71

  • P/E

    36.77

  • EV/EBITDA

    35.70

  • Debt/Equity (Industry)

    0.25

  • Interest Cover (Industry)

    11.42

  • ROCE (Industry)

    16.55

  • RONW (Industry)

    14.50

  • ROE

    5.43

  • ROCE

    6.72

  • Debt/Equity

    0.07

  • EPS (TTM)

    3.92

  • Dividend Yield

    0

  • Book Value

    68.42

  • Interest Cover

    16.50

Analysis

all

thumbs up icon

Pros

  • Colinz Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Colinz Laboratories is profitable, therefore cash runway is not a concern.
  • Colinz Laboratories is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (75.6%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 18.9x debt.
thumbs up icon

Cons

  • Unable to evaluate Colinz Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Colinz Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • High level of physical assets or inventory.
  • N.'s compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • The average tenure for the Colinz Laboratories management team is less than 2 years, this suggests a new team.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters66.0066.0066.0066.0066.00
FII00000
DII00000
Public34.0034.0034.0034.0034.00
Government00000

Read More

Technical Analysis

RSI

39.62

MACD

-3.55

50 DMA

53.27

200 DMA

47.24

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic143.55101.6474.4759.7332.5617.82-
Fibonacci101.6485.6375.7459.7343.7233.8317.82
Camarilla58.8254.9751.1359.7343.4539.6135.76

Pivots Level: Classic

R3

+83.82

143.55

R2

+41.91

101.64

R1

+14.73

74.47

59.73
59.73
Pivot Point
LTP: 42.95

S1

-27.18

32.56

S2

-41.91

17.82

S3

-59.73

-

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    43.23

  • 20-EMA

    45.99

  • 30-EMA

    47.98

  • 50-EMA

    49.50

  • 100-EMA

    49.38

  • 200-EMA

    49.37

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
24 Jan 2026board-meetingsQuarterly Results
03 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
31 Jul 2025agm
08 Aug 2024agm
31 Jul 2023agm
01 Aug 2022agm
30 Jul 2021agm

Read More

Peer Comparison

Colinz Laboratories Ltd logo

Colinz Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Colinz Laboratories Ltd About

Colinz Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations particularly in gynaecological sector.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1986

Headquarters

CEO

Employees

Contact

Website icon

Website

http://www.colinz.com

Email icon

Email

colinz@hathway.com; cllfindoc@yahoo.com

Phone icon

Phone

91-022-25668002/8003

Location icon

Location

A-101 Pratik Industrial Estate, Mulund Goregaon Link Road, Mumbai, Maharashtra, 400078

Read More

Colinz Laboratories Ltd Company History

YearHistory
1986
  • Colinz Laboratories Ltd. was incorporated as a private limited company.
  • The Company obtained certificate of registration No. 41128 on 16th October.
1990
  • The company started its production and marketing activities.
1995
  • The Company obtained Certificate of Change of name under the Companies Act, 1956 on 5th January.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GAURAV AGARWALBuy1633884.4630 Jan 2026
BONANZA PORTFOLIO LIMITEDBuy700086.9430 Jan 2026
F3 ADVISORS PRIVATE LIMITEDSell1474185.9430 Jan 2026
F3 ADVISORS PRIVATE LIMITEDBuy1474179.6830 Jan 2026
BONANZA PORTFOLIO LIMITEDSell1426078.330 Jan 2026
KEYUR SURESHBHAI SHAHBuy1370253.9909 May 2025
BHUPESH GUPTABuy1273180.9810 Jul 2024
KETAN BHAILAL SHAHBuy340006.8531 Jan 2007
KETAN BHAILAL SHAHSell340006.8531 Jan 2007

Read More

Colinz Laboratories Ltd News

Colinz Labs Q3FY26 Net Profit Rises 56.8% to ₹8.36 Cr

Colinz Laboratories reports Q3FY26 net profit of ₹8.36 crore, up 56.8% YoY. Revenue from operations stood at ₹143.41 crore with total comprehensive income reaching ₹16.29 crore for the quarter.

24 Jan 2026

co actions results

Colinz Labs: Promoter Shares Transmitted via Inheritance

Colinz Laboratories reports transmission of 8,67,750 equity shares (34.45% stake) from late Dr. Mani L.S. to his nominee Mrs. Vijaya Mani following his demise, with no change in overall promoter group holding.

13 Dec 2025

co actions results

Colinz Laboratories Appoints New Company Secretary and Authorizes Factory Sale Negotiations

Colinz Laboratories' board approved the appointment of Ms. Falguni Kumawat as Company Secretary and Compliance Officer effective December 1, 2025, and granted authority to CEO Narayan Kutty Menon to negotiate terms for the proposed sale of factory premises. The decisions affect the company's operational structure and asset management following prior shareholder approval for the property sale through a special resolution dated November 17, 2025.

27 Nov 2025

corporate governance

Colinz Laboratories Shareholders Approve Sale of Factory and Office Properties

Colinz Laboratories Limited shareholders approved two special resolutions through postal ballot to sell, lease, mortgage or dispose of the company's factory at Sinnar, Nashik and office at Mumbai. Both resolutions passed with 99.9996% votes in favor, with 61.0979% of total shares participating in the e-voting process conducted from October 15 to November 14, 2025.

17 Nov 2025

corporate action

Colinz Laboratories Appoints New Director Following Board Member's Death

Colinz Laboratories announced the death of Dr. Mani L.S., a Non-Executive Director, and appointed Mrs. Vijaya Mani as Additional Non-Executive Director effective November 11, 2025, subject to shareholder approval. The Board expressed condolences for Dr. Mani L.S., acknowledging his leadership and guidance to the company. Following these changes, the company reconstituted its board committees including Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, and Risk Management Committee, with Mrs. Vijaya Mani serving as Chairman of the Risk Management Committee. The appointments comply with SEBI regulations, and Mrs. Vijaya Mani has not been debarred from holding director positions.

11 Nov 2025

corporate governance

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800